I posted this on the other board and thought I would share
I posted this on the other board and thought I would share it here. It really applies to IHUB more than it does here.
Clearly, the large volume and drop in sp is due to people selling to participate in the warranty offer. I suspect the quick drop to .32 after the opening bell was due to an aggressive seller(s) who dropped the price several cents and triggered stop-loss orders that added fuel to the fire. And now there are a lot of nervous nellies who sit on the sidelines while the bashers add even more fuel to the fire.
Unless I missed a PR or video, what has changed since the annual shareholders meeting less than 2 weeks ago when everyone was so excited about the news? Now all I'm hearing is a lot of negative assumptions based on the "tone" of the CEO's voice in his last video, and negative assumptions based on the company extending a direct offering to other investors, and by a whole week. So now he's "groveling for pennies". Really?
Being a long-term investor in this stock, I FULLY understand the frustration level here, but one thing I won't do is undermine my investment by making a bunch of assumptions and bashing it on a message board. Instead, my message will go directly to the CEO and BOD where it will be heard by the decision makers. I would suggest you do the same.
6
CytoDyn Inc (CYDY) Stock Research Links
My comments are just my opinions and should NOT be taken as investment advice.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Investigation of Claims for Spyre Therapeutics Investors Pomerantz LLP is currently investigating claims on behalf of investors of Spyre Therapeutics, Inc. (NASDAQ: SYRE). The firm seeks to understand whether Spyre and its executives have potentially engaged in any unlawful business practices, specifically concerning securities fraud. Understanding the Securities Concerns...
Continue Reading
Natixis CIB's Role in Groundbreaking Project Financing Natixis Corporate & Investment Banking (Natixis CIB) has taken a significant step in enhancing infrastructure development by serving as Joint Bookrunner and Joint Lead Arranger for a remarkable $281 million project financing. This financing initiative will support Ruta del Este, a concessionaire formed by ISA Vías to...
Continue Reading
Finch Therapeutics Plans Delisting from Nasdaq Finch Therapeutics Group, Inc. (Nasdaq: FNCH) has recently announced its decision to delist from The Nasdaq Stock Market, LLC. This move is part of a broader strategy aimed at navigating current market challenges and optimizing operational efficiency. The company is a leader in microbiome technology, boasting a strong...
Continue Reading
Investigating the Latest Events Surrounding ModivCare Recent events surrounding ModivCare, Inc. have drawn considerable attention from the investor community and law firms alike. This scrutiny comes after a class action lawsuit from long-term shareholders, alleging the company's management may have misled investors about its ability to manage its financial health during a...
Continue Reading
A Call to Action for Avantor, Inc. Investors Investors in Avantor, Inc. should take heed of an essential notification regarding a securities class action. As a market participant interested in Avantor, Inc. (NYSE: AVTR), your involvement could be crucial. This class action centers around stock purchases made during a specific timeframe that is intended to hold the company...
Continue Reading